60 Degrees Pharmaceuticals, Inc. Files Form 8-K: Correction to Beneficial Ownership Disclosure

Key Points from the Report

• 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) filed a Form 8-K on March 20, 2026, disclosing a correction to previously reported beneficial ownership figures in its recent prospectus supplement.
• The company identified an error in the calculation of shares of common stock beneficially owned by an affiliate, which was originally disclosed in the prospectus supplement dated March 13, 2026.
• The number of shares beneficially owned by the affiliate was previously reported as 21,490 shares. The correct number is 23,367 shares.
• This error originated from an incorrect total share amount in a Form 4 filed on September 15, 2025, and was carried forward into subsequent filings, including a Form 4 filed on December 16, 2025, and ultimately into the prospectus supplement.
• The corrected total number of shares beneficially owned by the affiliate is now 16,781 shares, rather than the 15,905 shares previously reported, after accounting for a 1-for-4 reverse stock split.
• Except for the above correction, no other information in the prospectus supplement is affected.

Important Information for Shareholders

• Correction of Beneficial Ownership: The accurate reporting of share ownership is crucial for investors and can materially impact perceptions of insider holdings, control, and potential future transactions. Errors in such disclosures can be price sensitive, especially if they alter the perceived level of insider ownership or affect compliance with SEC regulations.
• Potential Impact on Share Price: The disclosure of a higher-than-reported affiliate shareholding may lead to increased investor scrutiny, possible changes in perceived insider confidence, and could affect the trading dynamics of the stock. Furthermore, the company’s prompt correction and transparency may be viewed positively by the market, but the initial error could raise concerns about internal controls and reporting accuracy.
• Reverse Stock Split: The numbers reported are post a 1-for-4 reverse stock split, which can also be significant for shareholder value and dilution calculations.
• No Other Changes: Shareholders should note that all other information in the prospectus supplement remains unchanged, mitigating broader risk from this correction.
• Trading Information:
  • Common Stock (par value \$0.0001 per share) trades under the symbol SXTP on NASDAQ.
  • Warrants to purchase one share of common stock trade under the symbol SXTPW on NASDAQ.
• Emerging Growth Company Status: 60 Degrees Pharmaceuticals, Inc. is classified as an Emerging Growth Company, as defined by SEC rules. The company has not elected to use the extended transition period for complying with new or revised financial accounting standards.

Detailed Article for Investors

On March 20, 2026, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) filed a Form 8-K with the U.S. Securities and Exchange Commission, announcing a correction to the beneficial ownership disclosure for one of its affiliates. This update pertains to the company’s recent prospectus supplement dated March 13, 2026.

The company discovered that the number of shares of common stock beneficially owned by an affiliate was incorrectly reported as 21,490 shares. The accurate figure should have been 23,367 shares. This discrepancy was traced back to an incorrect total share amount in a Form 4 filed on September 15, 2025, which was subsequently carried forward into later filings, including another Form 4 filed on December 16, 2025, and ultimately into the prospectus supplement.

After giving effect to the 1-for-4 reverse stock split, the corrected total number of shares beneficially owned by the affiliate is 16,781 shares, as opposed to the previously reported 15,905 shares. This correction is significant for shareholders, as it ensures accurate reporting of insider holdings, which can influence investor confidence, voting power, and potential future transactions.

The company emphasized that, aside from this correction, no other information in the prospectus supplement is affected. Investors should also note that 60 Degrees Pharmaceuticals, Inc. maintains its status as an Emerging Growth Company and has not opted for the extended transition period for new or revised financial accounting standards.

The company’s common stock and warrants continue to trade on the NASDAQ under the symbols SXTP and SXTPW, respectively. The correction to the beneficial ownership disclosure, while not affecting other aspects of the prospectus supplement, may be material to investor decisions, particularly those focused on insider activity and regulatory compliance.

Potential Price Sensitivity

This type of disclosure correction can be price sensitive. Accurate reporting of beneficial ownership is essential for market transparency and may influence investor sentiment. The fact that an insider holds more shares than previously reported could be interpreted as greater confidence in the company’s prospects, or, alternatively, could raise questions about the reliability of prior disclosures.

Disclaimer

This article is for informational purposes only and does not constitute financial advice, investment advice, or a recommendation to buy or sell securities. Investors should conduct their own due diligence and consult with a professional advisor before making any investment decisions. The contents are based on official filings and may be subject to further updates or corrections by the company or regulatory authorities.

View 60 DEGREES PHARMACEUTICALS, INC. Historical chart here